Protein tangles in Alzheimer's patients could help predict brain shrinkage

Research suggests tangles of tau could be used to predict how much shrinkage will occur and where

Tangles of a protein found inside the brain cells of people with Alzheimer’s disease can be used to predict future brain shrinkage, research suggests.

In healthy people, a protein called tau is important in supporting the internal structure of brain cells. However, in those with Alzheimer’s, chemical changes take place that cause the protein to form tangles that disrupt the cells. Such tangles have previously been linked to a loss of brain cells.

Now scientists have used imaging techniques to track the extent of tau tangles in the brains of those with early signs of Alzheimer’s, revealing that levels of the protein predict not only how much brain shrinkage will subsequently occur, but where.

“Our study supports the notion that tau pathology accumulates upstream of brain tissue loss and clinical symptoms,” said Prof Gil Rabinovici, a co-author of the research from the University of California, San Francisco.

A number of drugs targeting tau tangles are currently in clinical trials, including some that aim to interfere with the production of tau in the brain or its spread between cells.

Dr Renaud La Joie, another author of the research, said the findings suggested the imaging technique could prove valuable both in choosing which patients to enrol to test such drugs and in monitoring whether the drugs work.

Dr Laura Phipps, of Alzheimer’s Research UK, said: “The ability to track tau in the brain will be critical for testing treatments designed to prevent the protein causing damage, and the scans used in this study could be an important tool for future clinical trials.”

Writing in the journal Science Translational Medicine, La Joie and colleagues report how they used an imaging technique called positron emission tomography (Pet) to study the brains of 32 people aged between 49 and 83 who were in the early stages of showing Alzheimer’s symptoms.

Pet imaging involves injecting patients with a substance that contains a radioactive atom. The area in which the substance clusters shows up in subsequent scans.

The scientists used one substance that attaches to plaques of a protein in the brain known as beta amyloid, a hallmark of Alzheimer’s disease, and another recently developed substance that attaches to tau tangles.

They took a Pet scan at the start of the study, as well as an MRI, which reveals the structure of the brain. A second MRI was taken 15 months later to track brain atrophy.

The results reveal the level and location of tau tangles shown by the Pet scan at the outset were closely linked to shrinkage of grey matter in the brain, both in terms of the degree of shrinkage and its location. Such patterns explained about 40% of the variation in shrinkage. By contrast, there was little sign of a link between brain shrinkage and the extent of beta amyloid shown by Pet scan.

The findings held even when the thickness of the brain’s grey matter at the start of the study was taken into account, and when the age of participants was considered.

Although previous research has suggested brain atrophy shows a stronger link to tau tangles than beta amyloid, the team say the findings were still a surprise. “We were amazed by how well tau predicted not only the degree of atrophy overall, but the precise location of atrophy in individual patients,” said La Joie.

But, he added, the lack of a link to signs of beta amyloid does not mean those plaques are not harmful. “It is extremely rare to see significant amounts of tau tangles across the brain in patients with no amyloid: for some reason, amyloid seems almost necessary for tau to build up in the cortex,” said La Joie.

The study has limitations, including that the Pet scan gives only an indirect measure of levels of tau and beta amyloid, and the tracking substances might not bind only to those proteins.

“This relatively small study adds to evidence that tau may drive the death of brain cells, and could explain why symptoms get worse as tau spreads through the brain,” said Phipps. “While the majority of volunteers in the study were under the age of 65, making it harder to generalise the findings to everyone with the disease, the study highlights the importance of focusing future research efforts on the tau protein.”

• This article was amended on 3 January 2020 to give the full name of the imaging technique as positron emission tomography and to render it after first mention as Pet in accordance with style guidelines.

Contributors

Nicola Davis and Hannah Devlin

The GuardianTramp

Related Content

Article image
Alzheimer's link to herpes virus in brain, say scientists
Research reveals strains of virus more abundant in brains with early stage of disease, though uncertain whether virus is a trigger or a symptom

Hannah Devlin Science correspondent

21, Jun, 2018 @3:00 PM

Article image
Neurosurgery could spread protein linked to Alzheimer's, study finds
Doctors should decontaminate tools more thoroughly as a precaution, say researchers

Ian Sample Science editor

13, Dec, 2018 @4:04 PM

Article image
Alzheimer's may result from slow clearance of amyloid protein in brain

Brains that are inefficient at removing amyloid protein may be more susceptible to Alzheimer's disease, research suggests

Alok Jha, science correspondent

09, Dec, 2010 @7:00 PM

Article image
Trial shows tantalising signs that new Alzheimer's drug could benefit early-stage patients
Injections of the antibody aducanumab appear to slow condition in patients at earliest stages of disease, raising hopes for treatment

Ian Sample Science editor

31, Aug, 2016 @5:00 PM

Article image
A decade of deadlock over Alzheimer's treatment may be drawing to a close
The next phase of trials for a new Alzheimer’s drug will answer the real question: are brain plaques the root cause of the disease, or just a symptom?

Hannah Devlin Science correspondent

02, Nov, 2016 @6:57 PM

Article image
Brain cells grown in the lab will help to identify new Alzheimer's drugs

Embryonic stem cells can be used to create almost limitless supplies of the brain cell linked to memory loss in Alzheimer's

Ian Sample, science correspondent

04, Mar, 2011 @8:22 AM

Article image
Alzheimer's treatment within reach after successful drug trial
Tablet that ‘switches off’ production of toxic amyloid proteins could be first treatment licensed in a decade if it is also shown to slow mental decline

Hannah Devlin Science correspondent

02, Nov, 2016 @6:00 PM

Article image
Alzheimer's treatment closer as brain inflammation shown to be key
Study shows inflammation-reducing chemical prevents memory and behavioural problems in diseased mice, raising hopes for human treatment

Ian Sample Science editor

08, Jan, 2016 @12:05 AM

Article image
Ultrasound trial offers hope for brain cancer patients
New technique temporarily allows drugs to cross blood brain barrier to treat tumours

Linda Geddes

13, Oct, 2021 @5:00 PM

Article image
Protein linked to Alzheimer's could be spread during surgery, say researchers
Concern that tiny pieces of harmful proteins could be spread via surgical instruments leads scientists to call for more research into possible transmission

Ian Sample Science editor

09, Sep, 2015 @5:00 PM